Condition: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) · Sponsor: Mahidol University
The investigators of this registry aim to study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with ATTR amyloidosis in Thailand longitudinally. This will enable the investigators to study this disease in depth. With a better understanding, the investigators can aim to develop early screening programs for at-risk patients, raising awareness among non-cardiologists. As amyloid-specific therapies have now become available in Thailand, the findings of this registry can be helpful for epidemiological studies in Thailand.
This description comes directly from the study's public registry record.
Kanchalaporn Jirataiporn, B.N.S. · 0635153519 · kanchalaporn.jir@mahidol.ac.th
Always discuss trial participation with your own doctor first.
| Faculty of Medicine at Chulalongkorn University | Bangkok, Thailand | Not Yet Recruiting |
| Faculty of Medicine Ramathibodi hospital, Mahidol University | Bangkok, Thailand | Not Yet Recruiting |
| Faculty of Medicine Siriraj Hospital, Mahidol University | Bangkok, Thailand | Not Yet Recruiting |
| Phramongkutklao Hospital | Bangkok, Thailand | Not Yet Recruiting |
| Faculty of Medicine Chiang Mai University | Chiang Mai, Thailand | Not Yet Recruiting |
| Queen Sirikit Heart Center of The Northeast | Khon Kaen, Thailand | Not Yet Recruiting |
| Faculty of Medicine, Thammasat University | Pathum Thani, Thailand | Not Yet Recruiting |
| Prince of Songkla University | Songkhla, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06338696